FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281251314> ?p ?o ?g. }

• W4281251314 endingPage "385" @default.
• W4281251314 startingPage "379" @default.
• W4281251314 abstract "To investigate short-term treatment outcomes of intravitreal brolucizumab (IVBr) for treatment-naïve neovascular age-related macular degeneration (AMD) in a Japanese multicenter study.Retrospective case control study METHODS: The subjects were 58 eyes of 57 patients with neovascular AMD (43 men and 14 women, mean age 74.6 years) of whom 43 eyes of 42 patients completed initial loading of 3 monthly IVBr injections and were followed for more than 3 months. Best-corrected visual acuity (BCVA) changes, anatomical outcomes, and complications were investigated.Of the 43 eyes that completed loading doses, the AMD subtype was type 1 and type 2 macular neovascularization (MNV) in 51%, polypoidal choroidal vasculopathy (PCV) in 42%, and type 3 MNV in 7%. At 3 months after initiating treatment, BCVA significantly improved (P = 0.002) and central retinal thickness significantly decreased (P < 0.0001). At 3 months, complete retinal and subretinal fluid resolution was achieved in 91% of all eyes and complete regression of polypoidal lesions was achieved in 82% of PCV eyes. Iritis occurred in 8 eyes of 8 patients (14%), but resolved using topical or subtenon corticosteroid injection without visual loss in all cases.IVBr for treatment-naïve neovascular AMD was effective in the short-term, achieving significantly improved BCVA, good retinal fluid resolution, and a high rate of polypoidal lesion regression. However, iritis was noted in 14% of patients which may limit use of this drug." @default.
• W4281251314 created "2022-05-23" @default.
• W4281251314 creator A5000932487 @default.
• W4281251314 creator A5001102268 @default.
• W4281251314 creator A5003613652 @default.
• W4281251314 creator A5004999383 @default.
• W4281251314 creator A5011235917 @default.
• W4281251314 creator A5019490824 @default.
• W4281251314 creator A5021708656 @default.
• W4281251314 creator A5024277518 @default.
• W4281251314 creator A5028668037 @default.
• W4281251314 creator A5035944387 @default.
• W4281251314 creator A5036154382 @default.
• W4281251314 creator A5044619424 @default.
• W4281251314 creator A5045179653 @default.
• W4281251314 creator A5047407009 @default.
• W4281251314 creator A5049777361 @default.
• W4281251314 creator A5054730598 @default.
• W4281251314 creator A5066449873 @default.
• W4281251314 creator A5066685176 @default.
• W4281251314 creator A5069874619 @default.
• W4281251314 creator A5073831441 @default.
• W4281251314 creator A5078333939 @default.
• W4281251314 creator A5081069230 @default.
• W4281251314 creator A5083297413 @default.
• W4281251314 creator A5084684329 @default.
• W4281251314 date "2022-05-21" @default.
• W4281251314 modified "2023-10-14" @default.
• W4281251314 title "Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter study" @default.
• W4281251314 cites W1696340081 @default.
• W4281251314 cites W2007590058 @default.
• W4281251314 cites W2054180058 @default.
• W4281251314 cites W2107476817 @default.
• W4281251314 cites W2114441193 @default.
• W4281251314 cites W2331198753 @default.
• W4281251314 cites W2507305505 @default.
• W4281251314 cites W2936430874 @default.
• W4281251314 cites W2971436863 @default.
• W4281251314 cites W2988969159 @default.
• W4281251314 cites W2991331877 @default.
• W4281251314 cites W3017504588 @default.
• W4281251314 cites W3035836792 @default.
• W4281251314 cites W3040108021 @default.
• W4281251314 cites W3101914433 @default.
• W4281251314 cites W3104598671 @default.
• W4281251314 cites W3118577024 @default.
• W4281251314 cites W3126948741 @default.
• W4281251314 cites W3127081644 @default.
• W4281251314 cites W3131686561 @default.
• W4281251314 cites W3139212886 @default.
• W4281251314 cites W3155919247 @default.
• W4281251314 cites W3163314271 @default.
• W4281251314 cites W3175076164 @default.
• W4281251314 cites W3185440938 @default.
• W4281251314 cites W4207041227 @default.
• W4281251314 cites W4251857773 @default.
• W4281251314 doi "https://doi.org/10.1007/s10384-022-00922-3" @default.
• W4281251314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35595951" @default.
• W4281251314 hasPublicationYear "2022" @default.
• W4281251314 type Work @default.
• W4281251314 citedByCount "8" @default.
• W4281251314 countsByYear W42812513142023 @default.
• W4281251314 crossrefType "journal-article" @default.
• W4281251314 hasAuthorship W4281251314A5000932487 @default.
• W4281251314 hasAuthorship W4281251314A5001102268 @default.
• W4281251314 hasAuthorship W4281251314A5003613652 @default.
• W4281251314 hasAuthorship W4281251314A5004999383 @default.
• W4281251314 hasAuthorship W4281251314A5011235917 @default.
• W4281251314 hasAuthorship W4281251314A5019490824 @default.
• W4281251314 hasAuthorship W4281251314A5021708656 @default.
• W4281251314 hasAuthorship W4281251314A5024277518 @default.
• W4281251314 hasAuthorship W4281251314A5028668037 @default.
• W4281251314 hasAuthorship W4281251314A5035944387 @default.
• W4281251314 hasAuthorship W4281251314A5036154382 @default.
• W4281251314 hasAuthorship W4281251314A5044619424 @default.
• W4281251314 hasAuthorship W4281251314A5045179653 @default.
• W4281251314 hasAuthorship W4281251314A5047407009 @default.
• W4281251314 hasAuthorship W4281251314A5049777361 @default.
• W4281251314 hasAuthorship W4281251314A5054730598 @default.
• W4281251314 hasAuthorship W4281251314A5066449873 @default.
• W4281251314 hasAuthorship W4281251314A5066685176 @default.
• W4281251314 hasAuthorship W4281251314A5069874619 @default.
• W4281251314 hasAuthorship W4281251314A5073831441 @default.
• W4281251314 hasAuthorship W4281251314A5078333939 @default.
• W4281251314 hasAuthorship W4281251314A5081069230 @default.
• W4281251314 hasAuthorship W4281251314A5083297413 @default.
• W4281251314 hasAuthorship W4281251314A5084684329 @default.
• W4281251314 hasConcept C118487528 @default.
• W4281251314 hasConcept C141071460 @default.
• W4281251314 hasConcept C167135981 @default.
• W4281251314 hasConcept C168563851 @default.
• W4281251314 hasConcept C2776403814 @default.
• W4281251314 hasConcept C2778257484 @default.
• W4281251314 hasConcept C2780827179 @default.
• W4281251314 hasConcept C2781359195 @default.
• W4281251314 hasConcept C2992435398 @default.
• W4281251314 hasConcept C71924100 @default.
• W4281251314 hasConceptScore W4281251314C118487528 @default.

• next